Description
A Phase II Randomized Trial of Olaparib(NSC-747856) Administered Concurrently With Radiotherapy Versus RadiotherapyAlone for Inflammatory Breast Cancer
Thistrial is available at multiple Sutter Locations. Please contact one of the followingabout Study SWOG S1706
SanFrancisco: ClinicalResearch@sutterhealth.org
PaloAlto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
East Bay:James Nasman NasmanJ@sutterhealth.organd Vivian Leong, RN Leongv@sutterhealth.org
Sacramento:Isabel Rodrigues-Fong Rodrigi@sutterhealth.org andKirsten Babski babskik@sutterhealth.org
Modesto:Delia Massone MassonD@sutterhealth.organd Adrienne Palos PalosA@sutterhealth.org
Solano-VallejoCancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo:Stephanie Casal CasalSL@sutterhealth.org andBonnie Chan ChanBW@sutterhealth.org
Santa Rosa:Patricia Grinnell GrinneP@sutterhealth.org andMohammad Naseem NaseemMK@sutterhealth.org
View study details on ClinicalTrials.gov
Principal Investigator
Recruitment Status
Active, Recruiting
Start Date
July 12, 2019
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
Impact of COVID-19 on Cancer Care Management
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
POLARIS Palbociclib in Real World Practice
Investigators: Sivakumar Reddy, M.D., Rajeswari Chellappah, M.D., Kristie A. Bobolis, M.D., Kristin N. Arreola, M.D., Brian K. Kim, M.D, Vijay Suhag, M.D., Nitin Rohatgi, MD